HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ependymomas: a clinical and pathologic study. Part II. Survival features.

Abstract
A survival analysis of cases of ependymoma was performed. Patients with ependymomas of the infratentorium were found to have shorter disease-free intervals and to live for a shorter time after treatment than those with tumors of the cauda equina. Children with infratentorial tumors did not have a recurrence if they survived 3 or more years after operation, whereas adults with infratentorial tumors could have a first recurrence even 5 or more years after surgery. Younger patients did not survive as long as older patients in the group of infratentorial ependymomas. In contrast, age did not influence survival in patients with cauda equina ependymomas. Patients with ependymomas of the infratentorium and the cauda equina having long histories had a better prognosis than those with short histories. Changes in mitotic index and tumor cell number could not be correlated with the length of survival. In the infratentorial group, patients with rosette-bearing tumors had a poor prognosis, whereas patients with subependymal areas in their tumor had a better prognosis. Total surgical removal with no further treatment appeared to be as effective as subtotal removal followed by radiotherapy for the cauda equina tumors.
AuthorsE B Ilgren, C A Stiller, J T Hughes, D Silberman, N Steckel, A Kaye
JournalClinical neuropathology (Clin Neuropathol) 1984 May-Jun Vol. 3 Issue 3 Pg. 122-7 ISSN: 0722-5091 [Print] Germany
PMID6565537 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Adolescent
  • Adult
  • Aged
  • Brain Neoplasms (mortality, surgery)
  • Child
  • Child, Preschool
  • Ependymoma (mortality, surgery)
  • Female
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Peripheral Nervous System Neoplasms (mortality, surgery)
  • Spinal Cord Neoplasms (mortality, surgery)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: